Renin Feedback Is an Independent Predictor of Outcome in HFpEF.
RAAS
angiotensin
heart failure
outcome
renin
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
03 May 2021
03 May 2021
Historique:
received:
03
04
2021
revised:
25
04
2021
accepted:
28
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Drugs which interact with the renin angiotensin aldosterone system (RAAS) aim to reduce the negative effects of angiotensin (Ang) II. Treatment with these drugs anticipate a compensatory up-regulation of renin; however, it has been shown that there is a large variability in circulating plasma renin (PRA), even in patients with optimal medical therapy in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Our aim was to measure plasma renin activity (PRA-S), its response to RAAS inhibitor (RAASi) therapies and its effects on outcome in patients with HF with preserved ejection fraction (HFpEF). For this purpose, 150 HFpEF patients were included into a prospective single-center registry. Equilibrium (eq) angiotensin metabolites were measured from serum samples using mass spectroscopy. PRA-S (eqAng I + eqAng II) was calculated and compared in respect to the primary endpoint defined as all-cause death. PRA-S in patients with RAASi therapy was not significantly higher than in patients without RAASi (
Identifiants
pubmed: 34063595
pii: jpm11050370
doi: 10.3390/jpm11050370
pmc: PMC8147649
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Austrian Science Fund
ID : 246
Références
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Circ Res. 2015 Mar 13;116(6):960-75
pubmed: 25767283
Circ Res. 1991 Nov;69(5):1185-95
pubmed: 1834362
Eur J Heart Fail. 2020 Mar;22(3):458-468
pubmed: 31950651
Pharmacol Ther. 2008 Sep;119(3):311-25
pubmed: 18619489
J Hum Hypertens. 2009 Oct;23(10):683-6
pubmed: 19369955
Am J Hypertens. 2010 Sep;23(9):1014-22
pubmed: 20725057
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Nat Rev Drug Discov. 2002 Aug;1(8):621-36
pubmed: 12402502
Am J Hypertens. 1993 Sep;6(9):780-5
pubmed: 8110432
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Hypertension. 2000 Mar;35(3):710-6
pubmed: 10720583
Circulation. 2004 Oct 26;110(17):2618-26
pubmed: 15492298
Hypertension. 2019 Aug;74(2):285-294
pubmed: 31230551
Hypertension. 2004 Apr;43(4):785-90
pubmed: 15023936
Heart Fail Rev. 2020 Jan;25(1):31-42
pubmed: 31512149
Heart Fail Rev. 2019 May;24(3):367-377
pubmed: 30618017
J Am Coll Cardiol. 2017 Feb 21;69(7):805-819
pubmed: 28209222
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
Sci Rep. 2017 Mar 21;7:44911
pubmed: 28322341
J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S120-8
pubmed: 9892152
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
Hypertension. 2020 Jan;75(1):163-172
pubmed: 31760886
Clin Chem. 2020 Mar 1;66(3):483-492
pubmed: 32068832
J Am Coll Cardiol. 2016 Dec 27;68(25):2912-2914
pubmed: 28007153
Hypertension. 2001 Sep;38(3 Pt 2):635-8
pubmed: 11566946
Kidney Res Clin Pract. 2016 Dec;35(4):219-228
pubmed: 27957416
J Physiol. 1999 Oct 1;520 Pt 1:261-9
pubmed: 10517817
Clin Chem. 2018 Mar;64(3):597-608
pubmed: 29138270
Int J Cardiol. 2019 Dec 1;296:91-97
pubmed: 31443984
J Renin Angiotensin Aldosterone Syst. 2017 Jul-Sep;18(3):1470320317729919
pubmed: 28875746